It is indicated for adults with an initial BMI of 30 kg/m or greater, or 27 kg/m or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea
Overall, the multimorbidity of depression and T2DM involves shared genetic risk factors and multiple underlying biological mechanisms, including HPA axis dysregulation, pro-inflammatory states, gut-brain axis interactions, and insulin signaling alterations, which can affect neurotransmission
The drug acts on appetite-regulating centres in the brain, particularly in the hypothalamus, reducing hunger and increasing satiety. This leads to a natural reduction in food intake without forcing restrictive diets
A., Wharton, S., & STEP 5 Study Group (2022)